Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Investor Updates

11th Mar 2022 11:23

RNS Number : 5196E
Kanabo Group PLC
11 March 2022
 

Kanabo Group Plc

("Kanabo" or the "Company")

 

Investor Updates

 

Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company focussing on the development and distribution of cannabis-derived products for medical patients and wellness CBD consumers, has posted their latest investor newsletter and investor presentation to their website.

 

The latest Company presentation can be viewed here;

https://www.kanabogroup.com/wp-content/uploads/2022/03/Kanabo_GP_V01_230222.pdf

 

The Company has also posted a recent webinar with Vox Markets where Kanabo CEO, Avihu Tamir and GP Service CEO, Atul Devani discuss the GP Services acquisition. The webinar can be viewed here;

Watch the Kanabo webinar hosted by Vox Markets - Vox Markets

 

The latest Kanabo Investor Newsletter discussing the significant progress made over recent months can be viewed here; https://www.kanabogroup.com/press/foreword-from-the-ceo-march-11-2002/

 

 

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc

 

Avihu Tamir, CEO

Via Vox Markets

Peterhouse Capital Ltd

 

Eran Zucker (Financial Adviser)

Tel: +44 (0)20 7469 0930

Lucy Williams / Charles Goodfellow (Corporate Broker)

Tel: +44 (0)20 7469 0930

Vox Markets (Investor Relations)

 

Kat Perez

[email protected]

 

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKDBBDBKDBND

Related Shares:

Kanabo Grp Plc
FTSE 100 Latest
Value8,474.74
Change-133.74